1 / 15

Functional characterization of human Parainfluenza type 2 (hPIV-2) fusion glycoprotein mutants

Functional characterization of human Parainfluenza type 2 (hPIV-2) fusion glycoprotein mutants. Dr Manuel Rosa-Calatrava Dr Olivier Terrier Pr Bruno Lina. Jean-Christophe Le Bayon Master 2 GBC – 18 Juin 2009 UCBL. VirPath CNRS FRE 3011. The h PIV2. Mononegavirales Paramyxoviridae

haru
Download Presentation

Functional characterization of human Parainfluenza type 2 (hPIV-2) fusion glycoprotein mutants

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Functional characterization of human Parainfluenza type 2 (hPIV-2) fusion glycoprotein mutants Dr Manuel Rosa-Calatrava Dr Olivier Terrier Pr Bruno Lina Jean-Christophe Le Bayon Master 2 GBC – 18 Juin 2009 UCBL • VirPath • CNRSFRE 3011

  2. The hPIV2 • Mononegavirales • Paramyxoviridae • Rubulavirus • Virus responsible of Respiratory diseases • Enveloped virus Ø 200nm • Simple stranded RNA / negative polarity Terrier et al. (2008) • Entry into the cell possible with glycoproteinsF and HN

  3. Membrane Fusion Cellular membrane N C F2 S Fusion peptide S HR1 HN F Extracellular domain F1 HR2 Transmembrane region Cytoplasmic tail N C F HN Takimotoet al. (2002) Viral envelope

  4. Objectives • Terrier et al. (2008): hPIV-2 variants capable of an increased cell-cell fusion which carried the T96Amutation • Ito et al. (1998, 2009): when presenting L22P, K132Eand V290A PIV5 F becomes independent from HN • PIV5 / hPIV2 are very closed viruses We created mutants of the F GP hPIV2 which carried the mutations T96A and mutations transposed from PIV-5 in order to characterize their possible interaction on HN-F activation mechanism

  5. Methods • Bioinformatics and annotation of F hPIV2 • Cloning F and HN genes and directed mutagenesis • Flow cytometryand cell-cell luciferasefusion assay HuH7-TAT cell P TAT + substrate (luciferine) TAT Luc TAT Luc Fusion activate Luc Luc HIV-1 LTR Luc Luc P : constitutive promoter TAT : transcriptional activator pLUC: plasmid which carry : - LTR : TAT-dependant promoter - Luc: Firefllyluciferase gene Luc pLUCtransfected A549 cell

  6. Choice of mutations S-S F2 F1 PF TM C N HR1 HR2 I24P T96A K133E I294A SC 16 24 34 TGIVGSDAIAGDQLLNVGV TGIVGSDAIAGDQLLNIGV LAGAGSLDLAALMQIGVIP 14 22 32 86 96 106 PLIENLSKISAVTDTKPRRER PLIENLSKISTVTDTKTRQER F hPIV-2 variant F hPIV-2 Greer F PIV-5 VR-288 124 133 142 TITAAVAIVKANANAAAIN QITAAVAIVKANANAAAIN QVTAAVALVKANKNAAAIL 120 129 132 138 284 294 305MQPGAKVIDLIAISANHKLQEV MQPGAKVIDLIAISANHKLQEVVQPATQIIDLVTISAFINNQEV 280 290 301 F hPIV-2 variant F hPIV-2 Greer F PIV-5 VR-288

  7. T96A Mutation A B T96A is implicate into the HN promotion of fusion mechanism

  8. PIV-5 transposed mutations • Increased potential of fusion for I24P with or without HN A • K133E is very well expressed especially without HN • I294A permit an increased fusion only with HN as T96A B

  9. I24P based Mutations • I24P combination bring a better fusion effect also without HN A • With K133E big fusogenic characteristic, independent of HN B

  10. Conclusion • Mutant T96A is involved in a finest up-regulation of F by HN • The mutation I24P is involved in an increased “independence” of F • Mutants K133E and I24P-K133E may highlight another functional interaction between F and HN (down regulation) • I294A seems to have the same effect as T96A • Several parts of F seems to be involved in the F-HN interaction T96A K133E Head I24P I294A Neck

  11. Further investigations • Quantification of GP by Western-Blot • Finest membrane fusion quantification • Design an HN not able to promote the F GP • Behavior of a F mutant on a virus or a VLP (and mutant HN) • Evaluation of new clinical variants • Techniques: • Western-Blot/CoIP • Real-time lipid-mix assay • Virus-like particles with F and HN/Reverse genetics Design new moleculesagainst the hPIV-2 entry into the cells

  12. Acknowledgments Dr Olivier Terrier Dr Manuel Rosa-Calatrava Chrystelle for the “last-minute” cells All VirPath team for their support

  13. The Membrane Fusion Hickey et al. 2009

  14. CLUSTERING F F + HN

More Related